Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:47:06.405Z.
Calculation as of: 2026-10-06T18:47:06.405Z.
Quote observation: 2026-10-06T18:41:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f4beac4ac45f8a46ab4983c5a571fa9813be082d6d81805b5cbd768b9d0a60c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Lucyd, Inc
Market Cap
$5.79M
EV/EBITDA Ratio
N/A
Market Cap
$5.60M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Lucyd, Inc (LUCY) | $5.79M | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.79M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.82M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.01M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $5.85M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.66M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.60M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | N/A |
| Femasys Inc. (FEMY)vs › | $6.30M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.34M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
